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SUMMARY 
 
Background: Malignant pleural effusion (MPE) is increasing worldwide and 
prognostic biomarkers to plan treatment and to understand the underlying 
mechanisms of disease progression remain unidentified. The PROMISE study was 
designed with the objectives to discover, validate, and prospectively assess 
biomarkers of survival and pleurodesis response in MPE and build a score that 
forecasts survival.  
Methods: Five separate and independent datasets from randomized controlled trials 
(n = 597 patients) were used to investigate potential biomarkers of survival and 
pleurodesis. Mass spectrometry based discovery was used to investigate pleural 
fluid samples for differential protein expression in a discovery patient groups with 
different survival and pleurodesis outcomes. Clinical, radiological and biological 
variables were entered into least absolute shrinkage and selection operator 
regression to build a model that predicts 3-month mortality. The model was 
evaluated using internal and external validation.  
Findings: 16 and 7 biomarker candidates of survival and pleurodesis respectively 
were identified in the discovery dataset. Three independent datasets (n = 435) were 
used for biomarker validation. All pleurodesis biomarkers failed while GSN, MIF, 
VCAN and TIMP1 emerged as accurate predictors of survival. Eight variables 
(haemoglobin, c-reactive protein, white blood cell count, performance status, cancer 
type, pleural fluid TIMP1 levels and previous chemoradiotherapy) were validated and 
used to develop a survival score. Internal validation using bootstrap resampling and 
external validation using 162 patients from two independent datasets demonstrated 
good discrimination (c-index 0·78 and 0·89 respectively).  
Interpretation: The PROMISE score is the first prospectively validated prognostic 
model for MPE that combines biological and clinical parameters to accurately 
estimate 3-month mortality. 
Funding: European Respiratory Society, Medical Research Funding, Slater & 
Gordon Research Fund and Oxfordshire Health Services Research Committee 
Research Grants. 
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RESEARCH IN CONTEXT 
Evidence before this study:  
We searched PubMed for systematic reviews and studies with high throughput 
screening, retrospective analysis, development of clinical score and prospective 
validation of survival and treatment biomarkers in malignant pleural effusion 
published up to 5th of December, 2017, with the keywords “biomarkers”, “malignant 
pleural effusion (MPE)” ‘’survival’’ and ‘’pleurodesis’’. We applied search filters for 
“adult” and “English”. There were no studies that have been published and met our 
criteria. 
 
Currently the factors that drive and define malignant progression, resistance to 
therapy, and mortality in MPE are poorly understood. A prognostic model using 
clinical information in combination with blood and/or pleural fluid biomarkers that 
predicts survival and pleurodesis response would be of importance for clinical 
management and improve our understanding of MPE pathobiology 
 
Added value of this study 
This study, to our knowledge, is the first translational assessment combining 
discovery technology with high-quality clinical data from five different datasets for the 
development of a prognostic score for MPE. The results demonstrate the discovery, 
assessment and prospective validation of a novel prognostic score, including clinical 
data with pleural fluid biomarkers.  
 
Implications of all the available evidence 
There is now a compelling need for stratification of management of patients with 
MPE. A prognostic score predicting the 3-month risk of death will provide important 
information about patient prognosis and guide the selection of appropriate 
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management strategies. Additionally our results identify four biological pathways with 
the potential to guide novel treatments of MPE.  
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INTRODUCTION 
Malignant pleural effusion (MPE) is a common condition that annually affects 500-
700 individuals per million population1. The global cancer rate is rising, and with 
improvements in systemic therapy that allow many patients to live longer, the burden 
of MPE is increasing2-4. In addition to the clinical significance of MPE, dissemination 
of cancer cells in the pleural cavity is a biologic hallmark of highly metastatic 
malignancy regardless of the primary neoplasm, and current guidelines quote a 
median survival of three to 12 months1. Pleurodesis, the most common procedure 
used to treat MPE, prevents fluid accumulation through induction of pleural 
inflammation and fibrosis, succeeding in approximately 70% of patients assessed at 
one month1,5.  
 
In recent years, cancer treatment and pleural procedures available for MPE have 
expanded, leading to improved stratification of patients and progressive 
individualization of treatment, but also to diversification of outcomes such as 
pleurodesis success and survival6. However, the factors that drive and define 
malignant progression, resistance to therapy, and mortality in MPE are poorly 
understood. To this end, a prognostic model using clinical information in combination 
with blood and/or pleural fluid biomarkers that predicts survival and pleurodesis 
response would be of importance for clinical management, and would improve our 
understanding of MPE pathobiology. Such a risk stratification system was recently 
proposed: the LENT score predicts patients’ survival based on tumour type, pleural 
fluid lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) 
performance score, and blood neutrophil/lymphocyte ratio7. The LENT was 
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developed using clinical data from three existing patient cohorts combined with 
biochemical measurements of pleural fluid and has not been prospectively assessed.  
 
This study reports the development and validation of the survival and pleurodesis 
response markers in MPE (PROMISE), the first score dedicated to the prospective 
assessment of the survival of patients with MPE simultaneously employing clinical, 
biological, and radiological parameters. Data and samples from patients recruited to 
previously published multinational, multicentre clinical trials with identical and 
established recruitment criteria were used.  
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MATERIALS AND METHODS 
The study consisted of a three-step approach (discovery, validation, prospective 
assessment) that included Label Free Quantitative proteomic analyses of cell-free 
pleural fluid from a prospectively recruited cohort (biologic discovery), identification 
of prognostic clinical variables in published cohorts (clinical discovery), model 
development, model validation in two separate cohorts, and finally prospective 
assessment in two independent datasets from ongoing studies randomizing patients 
with MPE.  
Discovery and internal validation databases 
Clinical data and pleural fluid samples were used from three previous multicentre 
clinical trials, TIME-18, TIME-29, and TIME-310, which were prospectively collected 
between 2007 and 2016. Patients at the first onset of MPE were recruited on 
identical, clinically robust criteria from hospitals in the UK, USA, and Canada. 
Consistent data collected for each study participant included type of primary cancer, 
pleurodesis outcome, chest X-ray findings, pleural fluid LDH, performance status 
(ECOG), full blood count, haemoglobin, previous treatment (either with first line 
chemotherapy and/or radiotherapy), forced expiratory volume 1 (FEV1), and C-
reactive protein (CRP). Survival data for each patient was collected from the trials’ 
databases and cross-validated with a national registry.    
External validation databases 
Individuals from the Oxford Radcliffe Pleural Biobank and SIMPLE study11 were used 
for external validation of the prognostic score. Pleural fluid samples were 
prospectively collected alongside clinical data. In total, 158 samples were used for 
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the validation. The exact survival data for each patient was collected from the trial 
databases and cross-validated with a national registry.   
Pleural fluid analysis and mass spectrometry 
For biomarker discovery, a label free quantitative proteomic analysis 
(immunodepletion followed by Gel-Aided Sample Preparation (GASP)12 and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) was performed on TIME-2 
samples (total 114 patients) from 39 patients for the survival analysis (20 with poor 
and 19 with good survival) and from 26 patients (11 with failure and 15 with 
pleurodesis success) for the pleurodesis analysis. Samples were processed by 
depleting the top 12 high abundant proteins prior to digestion and analysed as per 
protocol (supplementary appendix page 3). Peptides were analysed by LC-MS/MS 
using a Q Exactive mass spectrometer (Thermo Scientific, Bremen, Germany) 
coupled with ultra-high performance liquid chromatography (Dionex Ultimate 3000 
UHPLC, Thermo) using a PepMap RSLC column (C18, 2 um, 100 A, 75 um x 50 
cm).  
Data were quantified in Progenesis QI for Proteomics (Nonlinear Dynamics).  
Peptide-spectrum matching was performed using Mascot (Matrix Science, UK) 
against the UniProt SwissProt database (retrieved 26/11/15) restricted to Homo 
sapiens taxonomy. Searches were performed using the following universal 
parameters - variable modifications: oxidation (M), propionamide (K), propionamide 
(N-term), fixed modifications: propionamide (C), precursor tolerance: 10 ppm, 
fragment tolerance: 0·05 Da, maximum missed cleavages: 1, up to 1 C13 Peaks 
considered. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
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identifier PXD008682. For further information please refer to the online 
supplementary appendix (page 3). 
Bioinformatics analysis of proteomic data 
Peptides were assigned to a specific protein, and different isoforms matched to the 
same protein. Three different bioinformatics groups analysed the data independently. 
R software (version 3) was used for the analysis of LC-MS/MS data13. The 
Bioconductor (release 3·6) packages Biobase14, limma15, and qvalue16 were used. 
Proteins identified with only one unique peptide and proteins detected in only three 
samples per condition were excluded from further analysis. Protein counts were log2 
transformed and subsequently normalised using the cyclicLoess algorithm. 
Independent t tests were used to identify statistically significant signals.  
Ingenuity pathway analysis 
To discover biological pathways related to survival and pleurodesis outcome the 
statistically significant proteins was subjected to pathway and upstream regulator 
analysis using the Ingenuity Pathway Analysis (IPA, spring release 2016) software 
(Qiagen Bioinformatics). 
Mass spectrometry protein validation with Elisa and Luminex 
Elisa and Luminex protein assays were performed to measure pleural fluid protein 
levels. Each protein was measured in technical triplicates per sample 
 
Statistical methodology for PROMISE score development 
Outcome measures 
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Two binary outcome measures were used; 1) Death before 3 months (91 days) from 
diagnosis for the survival analysis and 2) Pleurodesis success at 3 months, defined 
on objective and identical clinical criteria (see original publications for details)7,8.  
Candidate predictors 
A total of 25 candidate predictors were assessed, including baseline demographics 
(age and sex), malignancy type, prior chemotherapy or radiotherapy, severity of 
illness, serum laboratory values, and pleural fluid proteins. Candidate predictors 
were selected based on their biological role.  
Missing data 
There were no missing data for the outcome measures. Among the predictors, data 
were missing ranging from 0 to 62% (supplementary appendix page 5). Missing data 
were imputed via multiple imputation using the chained equations and predictive 
mean matching (with 50 imputations). All available data was included in the 
imputation score.  
Variable selection, model fitting, performance and discrimination 
A two-stage process was used, first to select variables for the final model, and then 
to estimate the coefficients for the final model. Due to the large number of candidate 
predictors relative to the number of deaths models were developed with Least 
Absolute Shrinkage and Selection Operator (LASSO) regression analysis using the 
GLMNET package in R (supplementary appendix page 3). Model discrimination was 
assessed using the c-statistic which quantifies the ability of model to differentiate 
between those who will die within 3 months, and those who will not. Model 
calibration was assessed through plots of the predicted versus observed mortality, 
and reporting of the calibration slope (which equals one for a perfectly calibrated 
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model). The Brier score was calculated as a general measure of predictive accuracy. 
Nagelkerke's R squared, a measure of overall performance was calculated. Each 
measure was calculated on each of the 50 imputed datasets after the second stage 
LASSO regression process. These performances were averaged to give the 
‘apparent’ model performance. 
Internal validation of PROMISE study model 
Internal validation of the model development process was carried out using a 
bootstrap resampling process to provide an unbiased estimate of model 
performance. The original dataset was resampled with replacement to obtain a 
dataset of the same size. The full modelling procedure was applied, including 
multiple imputations. Further information about the statistical methodology can be 
found in the online supplementary appendix (pages 3-4).   
Simplified model development 
Using the methods outlined by Sullivan et al17, a simplified version of the final model 
was created which was implementable in real life practice, whilst maintaining 
predictive performance and the ability to calculate absolute risk. All continuous 
predictors were categorised, and a reference value selected within each category, 
(usually the mid-point). Based on this, points were assigned to each category of 
each predictor. A simple table was produced to transform all possible total point 
scores into an absolute risk.  
External validation and LENT score calculation 
Using two independent and external datasets (the SIMPLE study11 and Oxford 
Pleural Biobank), the final PROMISE score was applied and used to calculate an 
absolute risk for each subject. Based on this risk, performance measures were 
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calculated. The LENT score7 was calculated in patients for direct comparison. The 
study was reported following the TRIPOD statement18.  
Statistics 
Data summarised using mean or median and standard deviation or interquartile 
range. Differential protein expression was assessed with either t-test or Mann–
Whitney U test (two-tailed P<0·05). Specific statistical methods used on candidate 
predictors’ selection or model development were described in previous sections. 
Analyses were done on the Statistical Package for the Social Sciences v24·0 (IBM, 
Armonk, NY) and Prism v7·0 (GraphPad, San Diego, USA). 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, writing of the report, or the decision to submit the manuscript for 
publication.  The corresponding author had full access to all the data in the study and 
carries the final responsibility for the decision to submit for publication.  
Ethical approval for the PROMISE study 
Ethical and regulatory approval for the study was obtained by the South Central 
Oxford A Research Ethics Committee (REC reference number 15/SC/0186). Ethics 
approval for sample analysis for external validation was obtained before the 
laboratory investigations (Oxford Radcliffe Biobank ethics committee reference 
17/A078). 
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RESULTS 
Generation of a MPE proteomic data set from the targeted interventions for 
malignant pleural effusion (TIME-2) discovery dataset identifies candidate 
biomarkers of survival and pleurodesis success 
The TIME-2 database was used for the discovery phase. Study participants were 
stratified based on survival and on pleurodesis outcome. For survival, patients were 
categorised as having poor (< 3 months) or good (≥ 3 months) survival based on 
median survival of the TIME-2 cohort (127 days) and on clinical decision for timing of 
providing best supportive care for MPE. The cut-off point of 3 months was selected 
based on clinical judgement, as there is paucity of data correlating days of survival 
that justify treatment with best supportive care instead of targeted treatment. 
Subjects were categorised to pleurodesis success or failure based on data at 3 
months post pleural intervention. Demographic characteristics are presented in 
supplementary appendix (page 7). In total, we identified 1,250 proteins (95% 
minimum protein probability and minimum of 2 peptides) and 1,150 proteins for the 
survival and pleurodesis groups respectively (Figures 1A, 1B). Detailed information 
for the LC-MS/MS data is given in online supplement. 393 proteins and 93 proteins 
were statistically significant (t-test False Discovery Rate adjusted p value for multiple 
comparisons: q-value<0·05) differentially expressed with an absolute fold change 
greater than 2 between patients with poor and good survival and patients with 
pleurodesis success and failure respectively.  
To corroborate the impact of the statistically significant differentially expressed 
proteins of the two datasets in an unbiased fashion, principal component analysis 
(PCA) was applied. In the survival dataset, the poor and good survival groups clearly 
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separated into two different clusters (Figure 1C). However, in the pleurodesis 
dataset, success and failure groups failed to separate and did not demonstrate 
distinct protein profiles (Figure 1D).  
For the survival analysis, nine of 393 statistically significant differentially expressed 
proteins were identified whose biological role signalled a probable biomarker 
potency: gelsolin (GSN), metallopeptidase inhibitor 2, fibulin 3, laminin beta 1, 
extracellular matrix protein 1, versican (VCAN), macrophage migration inhibitory 
factor (MIF), galectin 1, and galectin 3. For the pleurodesis analysis, three out of 93 
proteins were identified vascular cell adhesion protein 1 (VCAM1), matrix 
metalloproteinase 9 (MMP9), and angiopoietin-like 4 (ANGPTL4). 
Pathway and an upstream regulator analysis using the IPA software, of the 
statistically significant proteins were performed. For the survival dataset, eight 
proteins were detected with probable therapeutic utility based on their biological role: 
tissue inhibitor metalloproteinase 1 (TIMP1), platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), cadherin-1 (CDH1), interleukin 4 (IL4), 
hypoxia-inducible factor 1 alpha (HIF1a), fibulin 3 and osteopontin (secreted 
phosphoprotein 1, SPP1). For the pleurodesis dataset, four proteins were identified 
as potential biomarkers: tumour necrosis factor alpha, (TNFα), tumour necrosis 
factor beta (TNFβ), interleukin 6 (IL6), and fibroblast growth factor 2 (FGF2).  
Internal protein validation in the TIME-2 database of LC-MS/MS measured 
peptides 
To validate LC-MS/MS results, protein levels of candidate biomarkers of all TIME-2 
dataset samples were measured with either ELISA or Luminex assays 
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(supplementary appendix pages 7 and 8). For the survival analysis, we validated 
three of nine from the proteomic discovery experiment (GSN P=0.01, MIF P=0.03, 
and VCAN P=0.02). For the pleurodesis analysis, none of the candidate biomarkers 
could be validated (P > 0·05). 
External protein validation in the TIME-1 and TIME-3 datasets identifies GSN, 
MIF, VCAN and TIMP1 as robust biomarkers of survival in MPE 
To validate the biomarker utility of candidate proteins, expression was measured in 
two separate pleural fluid datasets (TIME-1 and TIME-3), which included 325 and 71 
study patients respectively. Patients were categorized based on survival and 
pleurodesis outcomes and all biomarkers validated in the TIME-2 database (LC-
MS/MS and IPA identified proteins) were measured in pleural fluid. All three proteins 
(GSN, MIF, and VCAN) from LC-MS/MS identified as prognostic biomarker 
candidates by LC-MS/MS showed a statistical significance in discriminating patients 
based on survival (Figure 2A-2D). A single upstream regulator protein from the IPA 
(TIMP1) showed differential expression that was statistically significant between the 
good and poor survival groups, whereas PDGF, VEGF, CDH1, IL4, HIF1a, FBLN 3, 
and SPP1 measurements did not differ significantly. All therapeutic (pleurodesis) 
biomarkers from the pathway analysis (TNFα, TNFβ, IL6, and FGF2) did not pass 
validation in the TIME-1 and TIME-3 datasets (P > 0·05).  
Clinical and biological PROMISE model development and performance 
We next sought to identify prognostic factors of survival in MPE. In the development 
dataset, 137/435 subjects died within 3 months (31%), and a total of 25 potential 
predictive factors including clinical, radiological (chest X ray findings) and biological 
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data (TIMP1, GSN, VCAN, MIF) were considered. For continuous risk factors, 
univariate analyses did not reveal any non-linear relationships with outcome. After 
LASSO regression, seven variables were retained in the final clinical score and eight 
in the biological score. After adjustment for optimism, the final clinical score achieved 
a C-statistic of 0·78, and included use of prior chemotherapy and radiotherapy, 
baseline performance status (PS), cancer type, haemoglobin, white cell count 
(WBC), C-reactive protein (CRP), and pleural fluid TIMP1 levels (Table 1). The 
biological score showed similar discrimination, with a C-statistic of 0·77, after 
adjusting for optimism. A simplified scoring system was derived for both the clinical 
and biological scores. (Table 2A and B). Both simplified scoring systems (clinical and 
biological) demonstrate good agreement with the full models (supplementary 
appendix pages 13 and 14). 
Prospective assessment of PROMISE score in SIMPLE and Pleural Biobank 
databases 
The external validation dataset comprised 162 subjects, of whom 58 died before the 
3 month hallmark (36%) using SIMPLE study and Pleural Biobank databases. 
Discrimination was high and similar for full and simplified PROMISE models, at 0·90 
(Table 1). Additionally, performance was similar for the full and simplified models. 
Both models were shown to be under-fitted, with calibration slopes greater than one 
(supplementary appendix pages 15 and 16). Based on the risk of three month death 
the PROMISE score can be classified to the following categories A: <25%, B: 25%-
<50%, C: 50%-<75% and D: ≥75%. A nomogram for each score (clinical, biological) 
is shown in supplementary appendix (page 17) 
Comparison of PROMISE with LENT score 
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The clinical and biological PROMISE scores and the LENT score were validated 
using complete case data, which included 192 subjects, of whom 62 died before 3 
months (33%). The C-statistic to discriminate between those who do or do not die 
before 3 months was 0·75 (95% CI 0.68-0·81) for the LENT score (supplementary 
appendix page 12). As the LENT score was developed using Cox-regression and not 
a logistic model, Harrell’s C-statistic was also calculated, and was 0·62 (95% CI 
0·58-0·66). Kaplan-Meier estimates demonstrated good discrimination of survival for 
all three models and revealed that PROMISE scores performed better than LENT 
despite lower sample sizes (Figures 3B-C).  
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DISCUSSION 
This is the first translational assessment combining discovery technology with high-
quality clinical data from five different datasets for the development of a prognostic 
score for MPE. The results demonstrate the discovery, assessment and prospective 
validation of a novel prognostic score, including clinical data with pleural fluid 
biomarkers.  
All parameters included in the PROMISE score are independently associated with 
survival, and thus the identified markers permit some speculation as to their 
biological role in survival in MPE. Those treated with previous chemotherapy and 
radiotherapy may have poorer prognosis due to the development of more aggressive 
cancer cell subpopulations that develop post-treatment. WBC and CRP are markers 
of systemic inflammatory responses, which are well associated with poor tumour-
specific immunity7,19. Decreased haemoglobin is likely to indicate a more advanced 
stage of disease20,21. Performance status and type of primary cancer are well known 
factors, which are associated with prognosis in all cancers7.  
This study has demonstrated that pleural fluid TIMP1 levels are associated with 
survival, even when all of the above clinical factors are accounted for. TIMP1 is a 
glycoprotein which regulates the structure of the extracellular matrix, and previous 
studies have suggested that TIMP1 promotes cellular proliferation and anti-apoptotic 
activity22-24. Alongside with TIMP1, GSN, VCAN and MIF have been identified as 
potential biological factors correlated with MPE survival. These factors may suggest 
novel potential therapeutic targets in MPE with preclinical data to support it.  
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The development of the PROMISE score is a significant step forward in the precise 
management of MPE and could potentially aid patients and clinicians by enabling 
selection of optimal management strategy of the effusion. Evidence suggest that 
clinical judgement alone is imprecise at estimating patient survival, highlighted by the 
fact that physicians are ineffective in excluding study participants with poor prognosis 
from large clinical trials8. Taken into consideration that future confirmatory studies 
are required, the PROMISE score (either clinical or biological) has the potential to be 
used in everyday clinical practice as a method to improve patient management, 
improve associated healthcare costs and as an enrichment strategy for future clinical 
trials. Individuals with a PROMISE score category A (with less than 25% absolute 
risk of death) correlates with a particularly good prognosis, and these patients could 
be selected for more aggressive pleural and potential oncological or surgical 
management.  In patients with a PROMISE score category D (at least 75% absolute 
risk of death), it is reasonable to offer minimally invasive procedures aimed at 
symptom control (e.g. therapeutic aspiration or indwelling pleural catheter insertion), 
best supportive care and a strategy to spend as few days as possible in hospital. 
Although clear recommendations cannot be given for patients with scores in 
categories B and C, the PROMISE study score provides a personalised absolute risk 
of death which will can be openly discussed during clinical consultation, and can be 
used as a basis for rational patient choices of further treatments offered.   
Although the same experimental design to identify biomarkers of pleurodesis 
outcome was deployed, this was not successful. These results highlight the 
importance of the validation process during the biomarkers development and could 
be explained by the fact that a high-throughput technique was only applied on pleural 
fluid samples before pleurodesis. In the future, a comparison of pleural fluid before 
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and after pleurodesis from the same patient would potentially provide more 
information for a pathway analysis and identify biomarkers of pleurodesis success. 
Currently a multicentre, multinational clinical trial11 is recruiting MPE patients that will 
provide samples before and after pleurodesis for further analysis.  
In addition to the prognostic score, the PROMISE study provides important 
information about the underlying biology of MPE and identifies four novel candidates 
likely involved in MPE pathogenesis (supplementary appendix page 18). LC-MS/MS 
data identified four proteins (TIMP1, GSN, VCAN, MIF) of significant importance in 
designing novel treatment targets. In light of the results, significant differences in the 
molecular pathways between patients with poor and good survival were identified. 
Four molecular pathways and upstream regulators that are differentially expressed in 
patients who had exceptional prognosis for MPE were demonstrated. There are 
existing experimental and clinical data regarding the potential impact of the upstream 
regulators, SPP1, FBLN 3, HIF1, and PDGF in MPE25-28. The results of PROMISE 
study suggest that further investigation is required to examine the potential clinical 
impact of inhibition of these molecular pathways.  
The strengths of this study include its design consisting of a three-step approach 
(discovery, validation, prospective assessment), a large sample size, and unique 
clinical resource with robust outcome data. Including all patients in the analysis and 
accounting for missing data using multiple imputations ensured all data were used 
and that potential missing associations were minimised. Prognostic scores were 
validated using two independent data sets, which add strength to the findings. 
Calculation of the PROMISE study score compared to current evidence (LENT 
score) provides an improved clinical prognostic score based on performance 
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(supplementary appendix page 12) and an advanced stratification score with 
personalised information for patients with MPE. Additionally, all variables that are 
included in the clinical PROMISE score are readily available in the clinical setting 
and measurement of TIMP-1 by the biochemistry department of a hospital can be 
achieved within 4 hours. In the real life situation when one parameter is missing, we 
would recommend using the last available measurement of the variable for the 
score. The important information that the PROMISE score provides compared to the 
LENT score justifies the extra variables that are required. 
There are limitations to this study. The derived score is only applicable to patients 
with confirmed MPE in whom a pleural procedure is intended, and this precluded the 
general applicability on patients with “paramalignant” effusion or suspected MPE. 
Information for time from cancer diagnosis and treatment post score calculation were 
not included in the multivariate analysis, however, all patients were recruited at the 
time of definitive pleural intervention, and this can be considered an important single 
point clinically. A biological factor was included in the score which potentially limits 
the pragmatic application of the PROMISE score in every hospital practice. To 
mitigate this, a simplified score using only clinical information has been proposed, 
with reasonable performance.   
To our knowledge this is the largest study in the literature with a systemic approach 
for identification of biomarkers and a prognostic score for MPE. The PROMISE study 
score is the first validated risk stratification system combining a discovered pleural 
fluid biomarker (TIMP1) with clinical information (previous chemotherapy or 
radiotherapy, haemoglobin, CRP, white cell blood count, performance status and 
type of primary cancer). It is therefore a robust, clinically relevant prognostic score 
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that can be applied immediately, and will provide important information on patient 
prognosis and guide the selection of appropriate management strategies. 
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FIGURE LEGENDS 
 
Figure 1. Proteomic analyses in the TIME-2 cohort. (A, B) Heatmaps of 
unsupervised hierarchical clustering for the survival (A) and pleurodesis (B) dataset 
samples. Red colour represents high expressive proteins and blue colour low 
expression proteins. (C) Principal component analysis (PCA) for the survival dataset. 
Red dots: Good Survival, Blue dots: Poor Survival. Interestingly, PCA separated the 
two groups into two different non-overlapping clusters. (D) PCA for the Pleurodesis 
dataset. Red dots: Failure, Blue dots: Success. Failure and Success groups failed to 
separate. 
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Figure 2. Validation of PROMISE components. (A-D) Relative protein expression 
(protein/total protein) of tissue inhibitor of metalloproteinase 1 (TIMP1, A), Gelsolin 
(GSN, B), Versican (VCAN, C), and macrophage inhibitory factor (MIF, D) in TIME-1, 
TIME-2 and TIME-3 datasets. (E-H) Selected clinical components of PROMISE in 
the TIME-1, TIME-2 and TIME-3 datasets. P, probability values for comparison 
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between long-term and poor survivors using t-test or Mann–Whitney U test (A-G) or 
chi square test (H). 
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Figure 3. Performance of LENT score and PROMISE score in malignant pleural 
effusion patients. (A) Kaplan-Meier survival curves from patients with low, medium 
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and high LENT score. (B) Kaplan-Meier survival curves from patients classified into 
PROMISE score categories for the clinical and (C) biological PROMISE score. 
PROMISE score categories: A: <25% (blue line), B: 25%-<50% (green line), C: 50%-
<75% (yellow line) and D: ≥75% (purple line). 
 
